ClinicalTrials.gg
CompletedNCT01362530Updated Sep 25, 2018Results posted

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)

A Phase 3 interventional study of Aprepitant 125 mg and Aprepitant 80 mg in Chemotherapy Induced Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2018-09-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.

Enrollment
10th of 61
307 · median 92
Started
2011
with 7 others
Phase 3
15 of 61
1 open now
Registered
33rd of 61
by date
Lead sponsor
9 of 61
Merck Sharp & Dohme LLC

Among the 61 studies testing aprepitant in Vomiting, this one is the 10th largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 3, and was the 33rd registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing aprepitant in Vomiting, or all of them as a file.
02

Study summary

This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours following the initiation of chemotherapy in pediatric participants. Those who complete this first cycle of treatment and meet certain eligibility criteria will have the option of continuing for 5 additional cycles of open-label aprepitant.

03

Conditions studied

  • Chemotherapy Induced Nausea and Vomiting

Browse trials for

04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cycle 1:

  • Is 6 months to 17 years of age at time of study entry
  • Is scheduled to receive chemotherapeutic agent(s) associated with moderate, high risk or very high risk of vomiting for a documented , or a chemotherapy regimen not previously tolerated due to vomiting
  • Is expected to receive ondansetron as part of their antiemetic regimen
  • If female and has begun menses, must has a negative urine pregnancy test prior to

randomization. A female who is of agrees to remain abstinent or use a barrier form of for at least 14 days prior to, throughout, and for at least one month following the last dose of study medication

  • If >10 years old, have a score ≥ 60; if ≤ 10 years have a Lansky Play Performance score ≥ 60
  • Have a predicted of ≥ 3 months

Optional Cycles 2-6:

  • Participant has, in the opinion of the investigator, completed the preceding cycle of chemotherapy and related study procedures satisfactorily

Exclusion criteria

Exclusion Criteria:

Cycle 1:

  • Has vomited in the 24 hours prior to Treatment Day 1
  • Is scheduled to receive stem cell rescue therapy in conjunction with study related course(s) of emetogenic chemotherapy
  • Has received or will receive radiation therapy to the abdomen or pelvis within a week prior to Treatment Day 1 or during the course of the study
  • Is pregnant or breast feeding
  • Is allergic to aprepitant, ondansetron, or any other 5-hydroxytryptamine type-3 receptor (5-HT3) antagonist
  • Has a symptomatic primary or CNS causing nausea and/or vomiting
  • History of or taking other medicinal products that lead to QT prolongation
  • Has an active infection (e.g., pneumonia), congestive heart failure, bradyarrhythmia, or any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction) except for malignancy, which in the opinion of the investigator, might confound the results of the study or pose unwarranted risk in administering study drug to the participant
  • Has had benzodiazepine or opioid therapy initiated within 48 hours of study drug administration, except for single daily doses of triazolam, temazepam, or midazolam
  • Has been started on systemic therapy within 72 hours prior to study drug administration or is planned to receive a corticosteroid as part of the chemotherapy regimen
  • Is currently taking warfarin

Optional Cycles 2-6:

  • All exclusion criteria from Cycle 1 apply except for vomiting in the 24 hours prior to Treatment Day 1
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    Aprepitant Regimen

    Cycle 1: Participants 12 to 17 years of age, Day 1: aprepitant 125 mg capsule orally (PO) + ondansetron, Days 2 to 3: aprepitant 80 mg capsule PO. Participants 6 months to \<12 years of age, Day 1: aprepitant powder for suspension (PFS), 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: aprepitant PFS, 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.

    Drug: Aprepitant 125 mg · Drug: Aprepitant 80 mg · Drug: Aprepitant powder for suspension (PFS) · Drug: Ondansetron · Drug: Emetogenic chemotherapy

  • Placebo comparator
    Control Regimen

    Cycle 1: Participants 12 to 17 years of age, Day 1: matching placebo for aprepitant 125 mg capsule oral (PO) + ondansetron Days 2 to 3: matching placebo for aprepitant 80 mg capsule PO. Participants 6 months to \<12 years of age, Day 1: matching placebo PFS: 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: matching placebo PFS: 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.

    Drug: Ondansetron · Drug: Placebo for Aprepitant 125 mg · Drug: Placebo for Aprepitant 80 mg · Drug: Placebo for Aprepitant PFS · Drug: Emetogenic chemotherapy

Interventions

  • On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age

    Also known as: MK-0869, Emend®

  • On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age

    Also known as: MK-0869, Emend®

  • DrugAprepitant powder for suspension (PFS)

    On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age

    Also known as: MK-0869, Emend®

  • Day 1: Administered according to product label for pediatric usage or local standard of care

    Also known as: Zofran™

  • DrugPlacebo for Aprepitant 125 mg

    On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age

  • DrugPlacebo for Aprepitant 80 mg

    On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age

  • DrugPlacebo for Aprepitant PFS

    On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age

  • DrugEmetogenic chemotherapy

    Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1

    Delayed Phase was defined as 25-120 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the delayed phase of Cycle 1.

    Time frame: 25 to 120 hours after the start of chemotherapy

Secondary outcomes

  1. Percentage of Participants With a Complete Response in the Acute Phase of Cycle 1

    Acute phase was defined as 0 to 24 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the acute phase of Cycle 1.

    Time frame: 0 to 24 hours after initiation of chemotherapy

  2. Percentage of Participants With a Complete Response in the Overall Phase of Cycle 1

    Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the overall phase of Cycle 1.

    Time frame: 0 to 120 hours after initiation of chemotherapy

  3. Percentage of Participants With No Vomiting in the Overall Phase of Cycle 1

    Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. No vomiting was defined as no emesis or retching or dry heaves in the overall phase of Cycle 1.

    Time frame: 0 to 120 hours after initiation of chemotherapy

07

Results

Posted Apr 4, 2014

Participant flow

Base Study (Cycle 1)
Participant flow — Base Study (Cycle 1)
MilestoneAprepitant RegimenControl Regimen
Started155152
Received study treatment152150
Completed150149
Not completed53
Withdrew: Adverse event20
Withdrew: Physician decision01
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject12
Optional Extension (Cycles 2-6)
Participant flow — Optional Extension (Cycles 2-6)
MilestoneAprepitant RegimenControl Regimen
Started1710
Completed460
Not completed1250
Withdrew: Adverse event20
Withdrew: Completed chemotherapy regimen510
Withdrew: Did not meet additional criteria250
Withdrew: Did not respond to chemotherapy regimen40
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up10
Withdrew: Physician decision190
Withdrew: Protocol violation40
Withdrew: Withdrawal by subject180

Outcome measures

PrimaryPercentage of Participants With a Complete Response in the Delayed Phase of Cycle 1

Delayed Phase was defined as 25-120 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the delayed phase of Cycle 1.

Time frame:
25 to 120 hours after the start of chemotherapy
Reported as:
Number · Percentage of participants
Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1
Percentage of participantsAprepitant RegimenControl Regimen
Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 150.726.0
Statistical analysis
  • Aprepitant Regimen vs Control Regimen · Cochran-Mantel-Haenszel · p = <0.01Stratified by age group, use of dexamethasone as an anti-emetic, and receipt of very high risk emetogenic chemotherapy.
SecondaryPercentage of Participants With a Complete Response in the Acute Phase of Cycle 1

Acute phase was defined as 0 to 24 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the acute phase of Cycle 1.

Time frame:
0 to 24 hours after initiation of chemotherapy
Reported as:
Number · Percentage of participants
Percentage of Participants With a Complete Response in the Acute Phase of Cycle 1
Percentage of participantsAprepitant RegimenControl Regimen
Percentage of Participants With a Complete Response in the Acute Phase of Cycle 166.452.0
Statistical analysis
  • Aprepitant Regimen vs Control Regimen · Cochran-Mantel-Haenszel · p = <0.05Stratified by age group, use of dexamethasone as an anti-emetic, and receipt of very high risk emetogenic chemotherapy.
SecondaryPercentage of Participants With a Complete Response in the Overall Phase of Cycle 1

Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the overall phase of Cycle 1.

Time frame:
0 to 120 hours after initiation of chemotherapy
Reported as:
Number · Percentage of participants
Percentage of Participants With a Complete Response in the Overall Phase of Cycle 1
Percentage of participantsAprepitant RegimenControl Regimen
Percentage of Participants With a Complete Response in the Overall Phase of Cycle 140.120.0
Statistical analysis
  • Aprepitant Regimen vs Control Regimen · Cochran-Mantel-Haenszel · p = <0.01Stratified by age group, use of dexamethasone as an anti-emetic, and receipt of very high risk emetogenic chemotherapy.
SecondaryPercentage of Participants With No Vomiting in the Overall Phase of Cycle 1

Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. No vomiting was defined as no emesis or retching or dry heaves in the overall phase of Cycle 1.

Time frame:
0 to 120 hours after initiation of chemotherapy
Reported as:
Number · Percentage of participants
Percentage of Participants With No Vomiting in the Overall Phase of Cycle 1
Percentage of participantsAprepitant RegimenControl Regimen
Percentage of Participants With No Vomiting in the Overall Phase of Cycle 146.721.3
Statistical analysis
  • Aprepitant Regimen vs Control Regimen · Cochran-Mantel-Haenszel · p = <0.01Stratified by age group, use of dexamethasone as an anti-emetic, and receipt of very high risk emetogenic chemotherapy.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aprepitant Regimen Cycle 1—46/152 (30.3%)88/152 (57.9%)
Control Regimen Cycle 1—41/150 (27.3%)84/150 (56%)
Aprepitant Regimen Cycles 2-6—84/170 (49.4%)136/170 (80%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventAprepitant Regimen Cycle 1Control Regimen Cycle 1Aprepitant Regimen Cycles 2-6
Febrile neutropeniaBlood and lymphatic system disorders23/15222/15053/170
AnemiaBlood and lymphatic system disorders2/1523/1509/170
VomitingGastrointestinal disorders2/1523/1508/170
PyrexiaGeneral disorders0/1522/1508/170
PancytopeniaBlood and lymphatic system disorders3/1526/1504/170
NeutropeniaBlood and lymphatic system disorders4/1520/1504/170
Neutrophil count decreasedInvestigations1/1522/1504/170
DehydrationMetabolism and nutrition disorders0/1521/1504/170
ThrombocytopeniaBlood and lymphatic system disorders0/1522/1503/170
Mucosal inflammationGeneral disorders2/1522/1503/170
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAprepitant Regimen Cycle 1Control Regimen Cycle 1Aprepitant Regimen Cycles 2-6
AnaemiaBlood and lymphatic system disorders24/15235/15062/170
VomiitingGastrointestinal disorders21/15220/15059/170
NauseaGastrointestinal disorders13/15217/15042/170
NeutropeniaBlood and lymphatic system disorders17/15218/15039/170
ThrombocytopeniaBlood and lymphatic system disorders15/15214/15038/170
Neutrophil count decreasedInvestigations12/15217/15032/170
Plastelet count decreasedInvestigations10/15215/15026/170
PyrexiaGeneral disorders8/15210/15022/170
CoughRespiratory, thoracic and mediastinal disorders9/1525/15018/170
Abdominal painGastrointestinal disorders11/15210/15017/170

Baseline characteristics

Intent-to-treat (ITT) population: all randomized participants who received study medication.

Age, Continuous
Age, Continuous(Months)Aprepitant RegimenControl RegimenTotal
Mean97.7 ± 63.299.4 ± 60.998.5 ± 62.0
Sex: Female, Male
Sex: Female, Male(Participants)Aprepitant RegimenControl RegimenTotal
Female6871139
Male8479163
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):385-94. doi: 10.1016/S1470-2045(15)70061-6. Epub 2015 Mar 12. Erratum In: Lancet Oncol. 2015 Sep;16(9):e427. doi: 10.1016/S1470-2045(15)00237-5. PubMed 25770814 ↗
  • Kang HJ, Loftus S, DiCristina C, Green S, Pong A, Zwaan CM. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. Pediatr Blood Cancer. 2018 Oct;65(10):e27273. doi: 10.1002/pbc.27273. Epub 2018 Jun 12. PubMed 29893452 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Mar 2013, 18 months.

Results were first posted in Apr 2014, 1 year after primary completion.

Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2011
First posted
May 30, 2011
StartActual
Sep 13, 2011
Primary completionActual
Mar 14, 2013
CompletionActual
Aug 16, 2013
Results first posted
Apr 4, 2014
Last update
Sep 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01362530
Responsible party
Sponsor
First posted
May 30, 2011
Start date
Sep 13, 2011
Primary completion
Mar 14, 2013
Completion
Aug 16, 2013
Results posted
Apr 4, 2014
Last update
Sep 25, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprepitant

Start the discussion